SCHEMBL279344

SCHEMBL279344

C=C(/N=C/c1cc(Br)ccc1Oc1ccc(C(F)(F)F)cc1)O[Si](C)(C)C

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SLC6A4 P31645 1/20 0.46
ATM Q13315 2/20 0.35
CYP1A2 P05177 2/20 0.35
CYP2C19 P33261 2/20 0.35
NPSR1 Q6W5P4 2/20 0.35
CYP3A4 P08684 1/20 0.35
CYP2D6 P10635 1/20 0.35
CYP2C9 P11712 1/20 0.35
HPGD P15428 4/20 0.34
L3MBTL1 Q9Y468 3/20 0.34
RAB9A P51151 1/20 0.34
TSHR P16473 1/20 0.34
THRB P10828 1/20 0.34
MAPT P10636 4/20 0.34
LMNA P02545 3/20 0.33
ALDH1A1 P00352 2/20 0.33
KDM4E B2RXH2 2/20 0.33
AMY1A P0DUB6 1/20 0.33
SMN1; SMN2 Q16637 2/20 0.33
KMT2A Q03164 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL279339 0.88 LMNA (0.40) CYP1A2CYP2C19CYP3A4CYP2D6CYP2C9
SCHEMBL279345 0.87 SLC6A4 (0.38) SLC6A4ATMHPGDL3MBTL1RAB9A
SCHEMBL279190 0.87 CCR5 (0.43) CYP1A2CYP2C19CYP2D6CYP2C9HPGD
SCHEMBL279202 0.81 HPGD (0.36) CYP1A2CYP2C19CYP3A4CYP2D6CYP2C9
SCHEMBL13929294 0.81 HPGD (0.44) CYP1A2CYP2C19CYP3A4CYP2D6CYP2C9
SCHEMBL278988 0.81 CCR5 (0.45) CYP1A2CYP2C19CYP2D6CYP2C9HPGD
SCHEMBL279179 0.78 LMNA (0.44) SLC6A4HPGDL3MBTL1MAPTLMNA
SCHEMBL275677 0.78 LMNA (0.44) SLC6A4HPGDL3MBTL1MAPTLMNA
SCHEMBL275218 0.78 HPGD (0.41) CYP1A2CYP2C19CYP3A4CYP2D6CYP2C9
SCHEMBL279119 0.77 HPGD (0.35) CYP1A2CYP2C19NPSR1CYP3A4CYP2D6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8134001-B2 Spiroindolinone derivatives HOFFMANN-LA ROCHE INC. (US) 2012-03-13 US disclosed
US-20090156610-A1 Spiroindolinone Derivatives DING QINGJIE 2009-06-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090156610-A1 Spiroindolinone Derivatives SDHA, AR, XPOT SLC6A4 2563/4885ATM 1296/4885CYP1A2 277/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.